CureVac N.V. (CVAC) is a biopharmaceutical company that develops and commercializes messenger RNA (mRNA) based therapeutics and vaccines. The company's product candidates are based on its proprietary mRNA technology platform, which enables the production of highly specific and effective protein therapeutics and vaccines. The company's lead product candidate is a COVID-19 vaccine, which is currently undergoing clinical trials.
CureVac was founded in 2000 and is based in Tubingen, Germany. The company completed its initial public offering in August 2020, raising approximately $245 million. CureVac has collaborations with several pharmaceutical and biotech companies, including Eli Lilly and Company, GSK, and Genmab, among others.
CureVac N.V. (CVAC) is a biopharmaceutical company that develops and commercializes messenger RNA (mRNA) based therapeutics and vaccines. The company's product candidates are based on its proprietary mRNA technology platform, which enables the production of highly specific and effective protein therapeutics and vaccines. The company's lead product candidate is a COVID-19 vaccine, which is currently undergoing clinical trials.